Prostate Cancer

Video Library — May 8, 2026

We are pleased to share our recent webinar on Metastatic Hormone-Sensitive Prostate Cancer. The webinar features Frank Dela Rama, RN, MS, AOCNS, AGN-BC (Clinical Nurse Specialist, Palo Alto, CA) and Kathryn Bowman, BS, RN, ONN-CG, OCN (GU/Neuro Navigator, Oncology, Winston-Salem, NC) discussing the biomarker testing landscape in prostate cancer as well as sharing their experiences and best practices to ensure patients receive biomarker testing at key treatment milestones. In addition, Frank and Kathryn discuss their best practices for recognizing and managing adverse events associated with the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).

Prostate Cancer in the Spotlight: A Teachable Moment to Increase Awareness

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

Prostate Cancer, Web Exclusives

June 2025 Vol 16, No 6 — May 27, 2025

With former President Joe Biden’s prostate cancer diagnosis being thrust onto the world’s stage, it is imperative that we use this as a teachable opportunity to educate people about the disease—and to highlight how oncology navigators make a difference in prostate cancer care.

IWTI 2021

Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer

Interview with the Innovators, Prostate Cancer

Interview with the Innovators – December 2021 — December 3, 2021

A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.

Diagnostic Capability in Relapsed Prostate Cancer Improved with ¹⁸F-DCFPyL PET/CT Imaging

Prostate Cancer

Web Exclusives — October 19, 2021

Recently released analysis of ¹⁸F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.

NaF PET Imaging Demonstrates Increased Sensitivity for New Lesion Detection for Patients with Metastatic Prostate Cancer

Prostate Cancer

Web Exclusives — October 19, 2021

NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.

Recent Study Results Finds ¹⁸F-Fluciclovine PET/CT Alters Recurrent Prostate Cancer Management

Prostate Cancer

Web Exclusives — October 19, 2021

Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after ¹⁸F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.

Multicenter International Prospective Trial on Gallium-68 PSMA PET/CT Imaging Confirms Accuracy in Detecting Prostate Cancer Recurrence

Prostate Cancer

Web Exclusives — October 19, 2021

Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.

Whole-Body MRI Found Superior to Bone Scan for Prognosis in Patients with Metastatic Prostate Cancer

Prostate Cancer

Web Exclusives — October 19, 2021

Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.

EMPIRE-1 Phase 2/3 Trial Results Indicate Fluorine 18 Fluciclovine PET/CT Utilization May Confer Event-Free Survival Advantage

Prostate Cancer

Web Exclusives — September 29, 2021

The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.

Recent Review Article Highlights PSMA-Based Radioligands Diagnostic Value in Prostate Cancer

Prostate Cancer

Web Exclusives — September 29, 2021

Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.

Researchers Released Data from a Clinical Trial Investigating Fluorine 18 Fluciclovine PET/CT Use to Identify Targets for Site-Directed Therapy

Prostate Cancer

Web Exclusives — September 29, 2021

Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.

Phase 3 INDICATE Trial Evaluating the Use of Apalutamide in Patients with Biochemical Recurrence of Prostate Cancer

Prostate Cancer

Web Exclusives — September 29, 2021

Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.

Androgen Deprivation Therapy at Time of Fluorine 18 Fluciclovine PET/CT More Likely to Return a Positive Scan

Prostate Cancer

Web Exclusives — September 29, 2021

Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.

The Nurse Navigator Role in the Treatment of Metastatic Castrate-Resistant Prostate Cancer: Highlights from an AONN+ Webinar Prostate Cancer

Prostate Cancer

September 2021 Vol 12, No 9 — September 16, 2021

Recent advances in the treatment of mCRPC include immunotherapies, such as sipuleucel-T, the first therapeutic cancer vaccine to receive approval from the US Food and Drug Administration.

Prostate Cancer

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.